Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vimizim Voucher A Result Of BioMarin’s Late Request, FDA Flexibility

Executive Summary

Sponsors of rare pediatric disease treatments should be buoyed by news that FDA’s Office of Orphan Products Development liberally interpreted the FDASIA language that requires priority review vouchers be given only when an indication is limited to a pediatric population.

You may also be interested in...



Sponsors May Race For Rare Pediatric Voucher Designations As Deadline Nears

US FDA program's new 2020 sunset could create a bolus of designation requests to ensure they can still get a voucher if it ends.

How Much Is A Priority Review Worth? $67.5 Million, Sanofi/Regeneron Say

Companies’ decision to purchase and redeem BioMarin’s priority review voucher for their PCSK9 inhibitor alirocumab sets the first public benchmark for a voucher’s value and shows the potential advantages to be gained for sponsors in a race to market.

BioMarin Tests FDASIA’s Pediatric Voucher Waters With Vimizim Approval

FDA clearance of the Morquio A syndrome treatment provides some insight into how the agency is implementing the 2012 priority review voucher program aimed at incentivizing development of treatments for rare pediatric diseases.

Topics

Related Companies

UsernamePublicRestriction

Register

PS056307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel